Studies have shown that p53-like bladder cancers are consistently resistant to NAC while cancers with mutations in fibroblast growth factor receptor 3 (FGFR3) may respond to targeted therapies, suggesting that the use of NAC may be aided by gene expression profiling [41]. The gene discussed is FGFR3; the disease is urinary bladder carcinoma.